Original Publication Date: 1 October, 2014
Publication / Source: Future Oncology
Authors: Maristella Saponara, Maria Abbondanza Pantaleo, Margherita Nannini, Guido Biasco
The advent of the tyrosine kinase inhibitors imatinib and sunitinib dramatically revolutionized the therapeutic approach to gastrointestinal stromal tumor (GIST) and improved the outcomes of patients who were affected by this rare tumor, becoming the standard first- and second-line systemic therapies for advanced/metastatic GIST. Most patients obtain good, durable responses to treatment; nevertheless, almost all patients develop acquired resistance, which is commonly related to secondary mutations in receptors.